Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls
- 1University of Alabama at Birmingham, Birmingham, AL USA
- 2City of Hope, Duarte, CA USA
- 3University of Minnesota, Minneapolis, MN USA
Abstract
Tyrosine kinase inhibitor (TKI) therapy has resulted in a significant reduction in chronic myeloid leukemia (CML)-related mortality. However, the impact of TKIs on the health status of long-term CML survivors remains unstudied. We examined the health status of 62 TKI-treated CML patients who did not receive blood or marrow transplantation (BMT) (CML_TKI; median follow-up: 12.5 y) compared with an unaffected population (303 non-CML controls), and CML patients treated with BMT but without TKI exposure (220 CML_BMT; median follow-up 19.4 y). Participants self-reported general health, functional status, activity limitations, and pre-frailty/frailty. Overall, 71.0% of CML_TKI participants had ≥1 adversely-affected domain vs. 42.6% of non-CML and 65.9% of CML_BMT participants. When compared with the non-CML controls, the CML_TKI cohort was more like to have poor general health (aOR = 4.43, 95%CI = 1.8–10.7), functional impairment (aOR=2.84, 95%CI = 1.4–6.0), and activity limitation (aOR=3.37, 95%CI = 1.7–6.7) and more likely to be frail/pre-frail (aOR=3.71, 95%CI = 1.7–8.1). The CML_TKI and CML_BMT cohorts were comparable with respect to poor general health (aOR = 0.95, 95%CI = 0.5–2.0), functional impairment (aOR = 1.59, 95%CI = 0.8–3.0), and pre-frailty/frailty (aOR = 1.92, 95%CI = 0.92–4.0), but the CML_TKI cohort was more likely to report activity limitation (aOR = 2.2, 95%CI = 1.1–4.5). These findings inform a need for long-term monitoring and development of risk mitigation strategies to improve the health status as a treatment goal in CML care.
Related
- The role of tyrosine kinase inhibitors as a post-hematopoietic stem cell transplant continuation therapy for pediatric acute leukemia: a systematic review
- Role and mechanism of ribosomal protein S3 in tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- LONGITUDINAL EXPRESSION OF MICRORNAS IN CHRONIC MYELOID LEUKEMIA FOLLOWING TYROSINE KINASE INHIBITOR DISCONTINUATION: POTENTIAL BIOMARKERS OF TREATMENT-FREE REMISSION
- EVOLUTION OF TYROSINE KINASE INHIBITOR USE AND MOLECULAR RESPONSE PATTERNS ACROSS LINES OF THERAPY IN CHRONIC MYELOID LEUKEMIA: REAL-WORLD EVIDENCE FROM BRAZIL
- A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma
BibTeX
@article{bhatia2026health,
title = {{Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls}},
author = {Smita Bhatia and Qingrui Meng and Lindsey Hageman and Sarah B. Palmer and Eunice E. Choe and Nora Balas and Wendy Landier and Omer Jamy and Pankit Vachhani and Alysia Bosworth and F. Lennie Wong and Jorge Cortes and Stephen J. Forman and Daniel J. Weisdorf and Saro H. Armenian and Ravi Bhatia},
journal = {Leukemia},
year = {2026},
month = aug,
doi = {10.1038/s41375-026-03123-w},
url = {https://doi.org/10.1038/s41375-026-03123-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls
AU - Smita Bhatia
AU - Qingrui Meng
AU - Lindsey Hageman
AU - Sarah B. Palmer
AU - Eunice E. Choe
AU - Nora Balas
AU - Wendy Landier
AU - Omer Jamy
AU - Pankit Vachhani
AU - Alysia Bosworth
AU - F. Lennie Wong
AU - Jorge Cortes
AU - Stephen J. Forman
AU - Daniel J. Weisdorf
AU - Saro H. Armenian
AU - Ravi Bhatia
PY - 2026
DA - 2026/08/21
JO - Leukemia
DO - 10.1038/s41375-026-03123-w
UR - https://doi.org/10.1038/s41375-026-03123-w
AB - Tyrosine kinase inhibitor (TKI) therapy has resulted in a significant reduction in chronic myeloid leukemia (CML)-related mortality. However, the impact of TKIs on the health status of long-term CML survivors remains unstudied. We examined the health status of 62 TKI-treated CML patients who did not receive blood or marrow transplantation (BMT) (CML_TKI; median follow-up: 12.5 y) compared with an unaffected population (303 non-CML controls), and CML patients treated with BMT but without TKI exposure (220 CML_BMT; median follow-up 19.4 y). Participants self-reported general health, functional status, activity limitations, and pre-frailty/frailty. Overall, 71.0% of CML_TKI participants had ≥1 adversely-affected domain vs. 42.6% of non-CML and 65.9% of CML_BMT participants. When compared with the non-CML controls, the CML_TKI cohort was more like to have poor general health (aOR = 4.43, 95%CI = 1.8–10.7), functional impairment (aOR=2.84, 95%CI = 1.4–6.0), and activity limitation (aOR=3.37, 95%CI = 1.7–6.7) and more likely to be frail/pre-frail (aOR=3.71, 95%CI = 1.7–8.1). The CML_TKI and CML_BMT cohorts were comparable with respect to poor general health (aOR = 0.95, 95%CI = 0.5–2.0), functional impairment (aOR = 1.59, 95%CI = 0.8–3.0), and pre-frailty/frailty (aOR = 1.92, 95%CI = 0.92–4.0), but the CML_TKI cohort was more likely to report activity limitation (aOR = 2.2, 95%CI = 1.1–4.5). These findings inform a need for long-term monitoring and development of risk mitigation strategies to improve the health status as a treatment goal in CML care.
SN - 0887-6924
SN - 1476-5551
ER -